长春高新：子公司GenSci145片境内生产药品注册临床试验申请获批

Core Viewpoint - Changchun High-tech announced that its subsidiary, Gensci Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial of GenSci145, a first-class innovative chemical drug intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1] Group 1 - The drug GenSci145 is designed to target PIK3CA mutations and has shown selective inhibitory activity against various PIK3CA hotspot mutations in preclinical studies, potentially addressing an unmet clinical need [1] - The approval marks a significant step in the drug's development, although the clinical trial process may face uncertainties [1] - The company will continue to advance its research and disclose progress in a timely manner [1]